U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C28H25F3N6O2
Molecular Weight 534.5334
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BGT-226 FREE BASE

SMILES

Cn1c2cnc3ccc(cc3c2n(-c4ccc(c(c4)C(F)(F)F)N5CCNCC5)c1=O)-c6ccc(nc6)OC

InChI

InChIKey=BMMXYEBLEBULND-UHFFFAOYSA-N
InChI=1S/C28H25F3N6O2/c1-35-24-16-33-22-6-3-17(18-4-8-25(39-2)34-15-18)13-20(22)26(24)37(27(35)38)19-5-7-23(21(14-19)28(29,30)31)36-11-9-32-10-12-36/h3-8,13-16,32H,9-12H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C28H25F3N6O2
Molecular Weight 534.5334
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22357447 | https://www.ncbi.nlm.nih.gov/pubmed/21959532

BGT 226 is an orally available, small molecule, the dual inhibitor of mammalian target of rapamycin (mTOR) and phosphatidylinositol 3'kinase (PI3K), developed by Novartis for the treatment of solid tumors, including advanced breast cancer. A phase I/II trial was completed in the US, Canada, and Spain, and a phase I trial was completed in Japan. However, development appears to have been discontinued.

Originator

Curator's Comment:: # Novartis

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.45 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BGT-226 MALEATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5.21 ng/mL
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BGT-226 MALEATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.5 ng/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BGT-226 MALEATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
26.97 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BGT-226 MALEATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
78.75 ng × h/mL
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BGT-226 MALEATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
32.86 ng × h/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BGT-226 MALEATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.61 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BGT-226 MALEATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8.62 h
125 mg single, oral
dose: 125 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BGT-226 MALEATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7.61 h
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BGT-226 MALEATE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Patients were received BGT226 (2.5, 5, 10, 20, 40, 80, and 125 mg) as a single oral daily dose, three times weekly (TIW) (every other day), 2 h after a light breakfast, and to continue fasting for two more hours. Treatment was continued on 28-day treatment cycles until unacceptable toxicity, disease progression, or consent withdrawal.
Route of Administration: Oral
HCC, Mahlavu, SNU475, SNU449, HepG2 and Hep3B cells were incubated in the presence of increasing concentrations of the BGT 226 for either 24 or 48 h. Cell viability rates were then analyzed by MTT assays. After 48 h of treatment cell viability impairment was evident, with an IC50 value ranging from 0.55 mkM for Mahlavu to 1.35 mkM for HepG2 cells
Substance Class Chemical
Created
by admin
on Sat Jun 26 15:35:32 UTC 2021
Edited
by admin
on Sat Jun 26 15:35:32 UTC 2021
Record UNII
ZXE7F2GMJJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BGT-226 FREE BASE
Common Name English
2H-IMIDAZO(4,5-C)QUINOLIN-2-ONE, 1,3-DIHYDRO-8-(6-METHOXY-3-PYRIDINYL)-3-METHYL-1-(4-(1-PIPERAZINYL)-3-(TRIFLUOROMETHYL)PHENYL)-
Systematic Name English
8-(6-METHOXYPYRIDIN-3-YL)-3-METHYL-1-(4-(PIPERAZIN-1-YL)-3-(TRIFLUOROMETHYL)PHENYL)-1H-IMIDAZO(4,5-C)QUINOLIN-2(3H)-ONE
Systematic Name English
Code System Code Type Description
EPA CompTox
915020-55-2
Created by admin on Sat Jun 26 15:35:33 UTC 2021 , Edited by admin on Sat Jun 26 15:35:33 UTC 2021
PRIMARY
PUBCHEM
11978790
Created by admin on Sat Jun 26 15:35:33 UTC 2021 , Edited by admin on Sat Jun 26 15:35:33 UTC 2021
PRIMARY
CAS
915020-55-2
Created by admin on Sat Jun 26 15:35:33 UTC 2021 , Edited by admin on Sat Jun 26 15:35:33 UTC 2021
PRIMARY
FDA UNII
ZXE7F2GMJJ
Created by admin on Sat Jun 26 15:35:33 UTC 2021 , Edited by admin on Sat Jun 26 15:35:33 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY